Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

Study summary

2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSmall RNA-based lung cancer assay

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 30, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?11 U.S. locations

Locations may change over time.

Who runs it?Hummingbird Diagnostics

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Hummingbird Diagnostics
Interventions being studied: Diagnostic Test: Small RNA-based lung cancer assay

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Surgery→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Adult male and female patients, aged 50 to 80 years
Received a lung RADS category 3 or 4 finding on a LDCT screening exam (first or subsequent) and are referred to undergo further diagnostic procedures for the detection of lung cancer
Has undergone LD-CT screening exam within last 90 days and allows for blood sampling within this period
Subject may not have undergone any invasive diagnostic procedure in relation to the suspicious nodule
Able and willing to provide informed consent

Reasons someone may not be able to joinExclusion criteria

Prior history of diagnosed lung cancer
History of gastrointestinal, hematological, breast, thyroid, and genitourinary cancer within the past 10 years
Active infectious diseases, such blood borne viral diseases (e.g. AIDS, hepatitis)
Immunosuppressive medication
Deemed not able to participate in the study by the investigator

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Northside HospitalAtlanta, Georgia
Our Lady of the Lake Regional Medical CenterBaton Rouge, Louisiana
Brigham and Women's HospitalBoston, Massachusetts
Mass General HospitalBoston, Massachusetts
UMass Chan Medical School/UMass Memorial HealthWorcester, Massachusetts
Henry Ford HealthDetroit, Michigan
New York Health + Elmhurst HospitalsQueens, New York
Jacobi Medical CenterThe Bronx, New York
Clinical Research Associates of Central PADuBois, Pennsylvania
Baptist Hospitals of Southeast TexasBeaumont, Texas
University Of Utah HealthSalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 30, 2026. Always confirm current availability with the study team.

View original record ↗